Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Launched by KAISER PERMANENTE · Sep 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two different flu vaccines in preventing influenza and related health issues in adults aged 65 and older. The two vaccines being compared are the quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) and the quadrivalent high-dose inactivated influenza vaccine (HD-IIV4). The trial will take place during the 2023/24 and 2024/25 flu seasons at Kaiser Permanente Northern California, where researchers will observe how well each vaccine works in protecting older adults from getting the flu and from complications like pneumonia and heart problems.

To be eligible for this study, participants need to be at least 65 years old and a member of Kaiser Permanente at the time of vaccination. They must receive either the aIIV4 or HD-IIV4 vaccine at a Kaiser facility during the designated flu seasons. Participants can expect to be part of a study that helps understand which vaccine is more effective, contributing to better flu prevention strategies for older adults. It’s important to note that those under 65 years old, those receiving the vaccine in a hospital, or anyone getting two flu shots in the same season won’t be eligible to join this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥65 years at the time of influenza vaccination
• • KPNC member at the time of vaccination
• • Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
• Exclusion Criteria:
• • Age \<65 years at the time of influenza vaccination
• • Received either aIIV4 or HD-IIV4 in the inpatient setting
• • Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
• • Receive an influenza vaccination outside of KPNC